TY - JOUR
T1 - Immunologic monitoring during OKT3 intervention in cyclosporine-treated renal allograft recipients
AU - Smith, W. J.
AU - Burdick, J. F.
AU - Pennington, L. R.
AU - Williams, G. M.
PY - 1986/1/1
Y1 - 1986/1/1
N2 - When patients are treated with OKT3, the immediate effect is removal of circulating T cells and reversal of rejection. As T cells recover from this treatment and begin to repopulate the peripheral circulation, relative levels of helper and suppressor/cytotoxic cells, as measured by the OKT4/OKT8 ratio, may be indicative of the future outcome of the graft. This repopulation situation, which occurs only with complete removal of circulating T cells by monoclonal antibody, is different from the complex immune status of allograft recipients at other times. In this current study, repopulation with normal (>1.2) ratios carried a good prognosis for successful graft outcome. On the other hand, repopulation with a low ratio indicated that re-rejection could result in graft failure. Treatment of cyclosporine-treated recipients with OKT3 can be beneficial in clarifying the nature of graft dysfunction. In addition, such treatment may provide insight into the immunobiology of the allograft response.
AB - When patients are treated with OKT3, the immediate effect is removal of circulating T cells and reversal of rejection. As T cells recover from this treatment and begin to repopulate the peripheral circulation, relative levels of helper and suppressor/cytotoxic cells, as measured by the OKT4/OKT8 ratio, may be indicative of the future outcome of the graft. This repopulation situation, which occurs only with complete removal of circulating T cells by monoclonal antibody, is different from the complex immune status of allograft recipients at other times. In this current study, repopulation with normal (>1.2) ratios carried a good prognosis for successful graft outcome. On the other hand, repopulation with a low ratio indicated that re-rejection could result in graft failure. Treatment of cyclosporine-treated recipients with OKT3 can be beneficial in clarifying the nature of graft dysfunction. In addition, such treatment may provide insight into the immunobiology of the allograft response.
UR - http://www.scopus.com/inward/record.url?scp=0022892336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022892336&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:0022892336
SN - 0041-1345
VL - 18
SP - 756
EP - 757
JO - Transplantation Proceedings
JF - Transplantation Proceedings
IS - 4
ER -